Survey of Ophthalmology
Volume 43, Issue 1 , Pages 3-18 , July 1998

Proliferative Vitreoretinopathy: An Overview

  • J.Carlos Pastor, MD

      Affiliations

    • Instituto Universitario de Oftalmobiologı́a Aplicada (IOBA), University of Valladolid, Valladolid, Spain
    • Corresponding Author InformationJ. Carlos Pastor, MD, IOBA, Facultad de Medicina, Ramón y Cajal, 7, 47005 Valladolid, Spain.

References 

  1. Abrams G, Glazer L. Proliferative vitreoretinopathy. In:  Freeman WR editors. Practical Atlas of Retinal Disease and Therapy. New York: Raven Press Ltd; 1993;p. 279–297
  2. Aguirrebeña A, Saornil MA, Giraldo A, Pastor JC. Incidencia de la vitreorretinopatı́a proliferante (VRP) en el desprendimiento de retina regmatógeno. Arch Soc Esp Oftalmol. 1986;51:229–234
  3. Algvere PV, Gjotterberg M, Olivestedt G, Fituri S. Results of pneumatic retinopexy with air. Acta Ophthalmol. 1992;70:632–636
  4. Alturki W, Peyman G, Paris C, et al.  Posterior relaxing retinotomies (Analysis of anatomic and visual results). Ophthalmic Surg. 1992;23:685–688
  5. Araiz JJ, Refojo MF, Arroyo M, et al.  Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1993;34:522–530
  6. Arroyo M, Refojo MF, Araiz JJ, et al.  Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy. Retina. 1993;13:245–250
  7. Baudouin C, Brignole F, Bayle J, et al.  Class II histocompatibility antigen expression by cellular components of vitreous and subretinal fluid in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1991;32:2065–2072
  8. Baudouin C, Fredj-Reygrobellet D, Gordon WC, et al.  Immunohistologic study of epiretinal membranes in proliferative vitreoretinopathy. Am J Ophthalmol. 1990;110:593–598
  9. Berger A, Cheng CK, Pearson PA, et al.  Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1996;37:2318–2325
  10. Berman DH, Gombos GM. Proliferative vitreoretinopathy (does low-dose colchicine have an inhibitory effect? A controlled study in humans). Ophthalmic Surg. 1989;20:268–272
  11. Binder S, Bonnet M, Velikay M, et al.  Radiation therapy in proliferative vitreoretinopathy. A prospective randomized study. Graefes Arch Clin Exp Ophthalmol. 1994;232:211–214
  12. Blumenkranz MS, Azen SP, Aaberg T, et al.  Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 5. Am J Ophthalmol. 1993;116:557–564
  13. Blumenkranz MS, Hernandez E, Ophir A, Norton EWD. 5-Fluorouracil (new applications in complicated retinal detachment for an established antimetabolite). Ophthalmology. 1984;91:122–130
  14. Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982;94:458–467
  15. Bonnet M. Macular changes and fluorescein angiographic findings after repair of proliferative vitreoretinopathy. Retina. 1994;14:404–410
  16. Bonnet M. Clinical findings associated with the development of postoperative PVR in primary rhegmatogenous retinal detachment. In:  Heimann K,  Wiedemann P editor. Proliferative Vitreoretinopathy. Heidelberg: Kaden; 1989;p. 8–20
  17. Bonnet M. Clinical factors predisposing to massive proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Ophthalmologica (Basel). 1984;188:148–152
  18. Bonnet M, Guenoun S. Surgical risk factors for severe postoperative proliferative vitreoretinopathy (PVR) in retinal detachment with grade B PVR. Graefes Arch Clin Exp Ophthalmol. 1995;233:789–791
  19. Bourke RD, Cooling RJ. Vascular consequences of retinectomy. Arch Ophthalmol. 1996;114:155–160
  20. Broekhuyse RM, Rademakes AJ, Van Vugt AH, Winkens HJ. Autoimmune responsiveness to retinal IRBP, S-antigen and opsin in proliferative vitreoretinopathy. Exp Eye Res. 1990;50:197–202
  21. Campochiaro PA, Bryan JA, Conway BP, Jaccoma EH. Intravitreal chemotactic and mitogenic activity (Implications of blood-retinal barrier breakdown). Arch Ophthalmol. 1986;104:1685–1690
  22. Campochiaro PA, Glaser BM. Platelet derived growth factor is chemotactic for human retinal pigmented epithelial cells. Arch Ophthalmol. 1985;103:576–579
  23. Campochiaro PA, Jerdan JA, Glaser BM. Serum contains chemoattractants for human retinal epithelial cells. Arch Ophthalmol. 1984;102:1830–1833
  24. Casaroli R, Vilaró S. The role of fibronectin, laminin, vitronectin and their receptors on cellular adhesion in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1994;35:2791–2803
  25. Chandler DB, Hida T, Sheta S, et al.  Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol. 1987;225:259–265
  26. Chang S. Low viscosity liquid fluorochemicals in vitreous surgery. Am J Ophthalmol. 1987;103:38–43
  27. Chang S, Lincoff H, Zimmerman NJ, et al.  Giant retinal tears (Surgical techniques and results using perfluorocarbon liquids). Arch Ophthalmol. 1989;107:761–766
  28. Chang S, Zimmermman NJ, Iwamoto T, et al.  Experimental vitreous replacement with perfluorotributylamine. Am J Ophthalmol. 1987;103:29–37
  29. Chapman C, Iverson D, Hartzer M, et al.  The effect of low-molecular-weight heparin on proliferative vitreoretinopathy induced in the rabbit eye (abstract). Invest Ophthalmol Vis Sci. 1992;33(Suppl):855
  30. Charteris DG. Proliferative vitreoretinopathy (pathobiology, surgical management, and adjunctive treatment). Br J Ophthalmol. 1995;79:953–960
  31. Charteris DG, Hiscott P, Grieson I, Lightman S. Proliferative vitreoretinopathy. Lymphocytes in epiretinal membranes. Ophthalmology. 1992;99:1364–1367
  32. Charteris DG, Hiscott P, Robey HL, et al.  Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. Ophthalmology. 1993;100:43–46
  33. Christmas NJ, Skolik SA, Howard MA, et al.  Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology. 1995;102:263–271
  34. Coleman DJ, Lucas BC, Fleischmann JA, et al.  A biologic tissue adhesive for vitreoretinal surgery. Retina. 1988;8:250–256
  35. Cowley M, Conway BP, Campochiaro PA, et al.  Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol. 1989;107:1147–1151
  36. Daniels S, Coonley K, Yoshizumi M. Taxol treatment of experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1990;228:513–516
  37. Davis AA, Whidby DE, Privette T, et al.  Selective inhibition of growing pigment epithelial cells by a receptor-direct immunotoxin. Invest Ophthalmol Vis Sci. 1990;31:2514–2519
  38. De Juan E, McCuen BW. Management of anterior vitreous in proliferative vitreoretinopathy. Retina. 1989;9:258–261
  39. Diddie K, Azen S, Freeman H, et al.  Anterior proliferative vitreoretinopathy in the silicone study. Silicone Study Report Number 10. Ophthalmology. 1996;103:1092–1099
  40. Eckardt C, Behrendt S, Zwick A. Results of silicone oil removal from eyes treated with retinectomies. Ger J Ophthalmol. 1992;1:2–6
  41. Elner S, Elner VM, Jaffe G, et al.  Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res. 1995;14:1045–1053
  42. Federman JL, Eagle RC. Extensive peripheral retinectomy combined with posterior 360° retinotomy for retinal reattachment in advanced proliferative vitreoretinopathy cases. Ophthalmology. 1990;97:1305–1320
  43. Federman JL, Schubert HD. Complications associated with the use of silicone oil in 150 eyes after retina-vitreous surgery. Ophthalmology. 1988;95:870–876
  44. Garcı́a-Layana A, Gonzalez G, Saornil MA, et al.  Papel del factor de crecimiento derivado de las plaquetas (PDGF) en un modelo experimental de VRP en el cerdo. Arch Soc Esp Oftalmol. 1995;68:123–130
  45. Garcı́a-Layana A, Hernando MT, Manzanas L, Pastor JC. Tratamiento profiláctico de la vitreoretinopatı́a proliferante. Arch Soc Esp Oftalmol. 1991;60:315–322
  46. Garcı́a-Layana A, Pastor JC, Saornil MA, Gonzalez G. Porcine model of proliferative vitreoretinopathy with platelets. Curr Eye Res. 1997;16:556–563
  47. Gilbert CE. Adhesives in retinal detachment surgery. Br J Ophthalmol. 1991;75:309–310
  48. Girard P, Mimoun G, Karpouzas I, Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina. 1994;14:417–424
  49. Glaser BM. Surgery for proliferative vitreoretinopathy. In:  Ryan SJ editors. Retina. 2. St Louis: CV Mosby; 1994;p. 2265–2280
  50. Glaser BM, Lemor M. Pathobiology of proliferative vitreoretinopathy. In:  Ryan SJ editors. Retina. 2. St Louis: CV Mosby; 1994;p. 2249–2263
  51. Glaser BM, Michels RG, Kuppermann BD, et al.  Transforming growth factor-β2 for the treatment of full-thickness macular holes. A prospective randomized study. Ophthalmology. 1992;99:1162–1173
  52. Glaser BM, Vidaurri-Leal J, Michels R, Campochiaro PA. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology. 1993;100:466–470
  53. Goldaracena MB, Garcı́a-Layana A, De la Fuente LF, et al.  Estudio inmunocitoquı́mico de las membranas perirretinianas en un modelo experimental de vitreoretinopatı́a proliferante (VRP). Arch Soc Esp Oftalmol. 1992;63:519–524
  54. Goldaracena MB, Garcı́a-Layana A, Pastor JC, et al.  The role of retinotomy in an experimental model of proliferative vitreoretinopathy. Curr Eye Res. 1997;16:422–427
  55. Goldaracena MB, Pastor JC, Saornil MA, et al.  Creación de un modelo eficaz de VRP. Arch Soc Esp Oftalmol. 1994;67:127–134
  56. Goldaracena MB, Piñon R, Garcı́a A, et al.  Efecto de la inyección intravı́trea de factores plaquetarios asociados a la crioaplicación y su relación con la VRP. Arch Soc Esp Oftalmol (Invest). 1990;3:161–168
  57. Gonvers M. Temporary silicone oil tamponade in the management of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1985;100:239–245
  58. Gremillion C, Peyman G, Liu K, Naguib K. Fluorosilicone oil in the treatment of retinal detachment. Br J Ophthalmol. 1990;74:643–646
  59. Grisanti S, Heimann K, Wiedemann P. Immune response to specific molecules of the retina in proliferative vitreoretinal disorders. Graefes Arch Clin Exp Ophthalmol. 1994;232:302–307
  60. Grisanti S, Heimann K, Wiedemann P. Origin of fibronectin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy. Br J Ophthalmol. 1993;77:238–242
  61. Guerra A, Manzanas L, Giraldo A, et al.  Resultados de las inyecciones de SF6 como tratamiento del desprendimiento de retina. Arch Soc Esp Oftalmol. 1987;53:393–398
  62. Hanneken A, Baird A. Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid. Invest Ophthalmol Vis Sci. 1995;36:1192–1196
  63. Hart PH, Vitti GF, Burgess DR, et al.  Potential antiinflammatory effects of interleukin 4 (Suppression of human monocyte tumor necrosis factor-β, interleukin-1, and prostaglandin-E2). Proc Natl Acad Sci U S A. 1989;86:3803–3807
  64. Haut J, Seigle P, Larricart P, et al.  Circular subtotal retinectomy and inferior semicircular retinotomy (Preliminary report). Ophthalmologica. 1985;191:65–74
  65. Hermsen LM, Fulcher SF, Soiekerman AM, et al.  Long-term inhibition of cellular proliferation by immunotoxins. Arch Ophthalmol. 1990;198:1009–1011
  66. Hernaez C, Saornil MA, Pastor JC, et al.  Estudio experimental de la vitreorretinopatı́a proliferante. Comparación entre dos modelos. Arch Soc Esp Oftalmol. 1990;58:233–242
  67. Hiscot PS, Grierson I, McLeod D. Retinal pigment epithelial cells in epiretinal membranes (An immunohistochemical study). Br J Ophthalmol. 1984;68:708–715
  68. Immonen I, Tervo K, Virtanen I, et al.  Immunohistochemical demonstration of cellular fibronectin and tenascin in human epiretinal membranes. Acta Ophthalmol. 1991;69:466–471
  69. Iverson DA, Katsura H, Hartzer MK, Blumenkranz MS. Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy. Arch Ophthalmol. 1991;109:405–409
  70. Iverson DA, Ward TG, Blumenkranz MS. Indications and results of relaxing retinotomy. Ophthalmology. 1990;97:1298–1304
  71. Johnson R, Blankenship G. A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin. Ophthalmology. 1988;95:312–317
  72. Johnston R. Immunology (Monocytes and macrophages). N Engl J Med. 1988;318:747–752
  73. Koerner F, Merz A, Gloor B, Wagner E. Postoperative retinal fibrosis—a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol. 1982;219:268–271
  74. Kono T, Kohno T, Inomata H. Epiretinal membrane formation. Light and electron microscopic study in an experimental rabbit model. Arch Ophthalmol. 1995;113:359–363
  75. Kuratsu J, Ushio Y. Antiproliferative effect of trapidil, a platelet-derived growth factor antagonist, on a glioma cell line in vitro. J Neurosurg. 1990;73:436–440
  76. Kuriyama S, Ohuchi T, Yoshimura N, et al.  Evaluation of radiation therapy for experimental proliferative vitreoretinopathy in rabbits. Graefes Arch Clin Exp Ophthalmol. 1990;228:552–555
  77. Lazarus HS, Russell SR, Zahn S, Hageman GS. Histochemical evidence for vitreous hyalocytes as components of pathological vitreous membranes (abstract). Invest Ophthalmol Vis Sci. 1992;33(Suppl):58
  78. Lean JS, Stern WH, Irvine A, Azen SP. The Silicone Study Group. Classification of proliferative vitreoretinopathy used in the Silicone Study. Ophthalmology. 1989;96:756–771
  79. Ligget PE, Skolik SA, Horio B, et al.  Human autologous serum for the treatment of full-thickness macular holes. Ophthalmology. 1995;102:1071–1076
  80. Limb GA, Little BC, Meager A, et al.  Cytokines in proliferative vitreoretinopathy. Eye. 1991;5:686–693
  81. López MI, Alonso I, Saornil MA, et al.  Análisis experimental de la reacción inflamatoria provocada por las siliconas fluoradas a nivel intraocular. Arch Soc Esp Oftalmol (invest). 1989;2:149–154
  82. Lopez R, Chang S. Long-term results of vitrectomy and perfluorocarbon gas for the treatment of severe proliferative vitreoretinopathy. Am J Ophthalmol. 1992;113:424–428
  83. Lucke KH, Föester MH, Laqua H. Long-term results of vitrectomy and silicone oil in 500 cases of complicated retinal detachments. Am J Ophthalmol. 1987;104:624–633
  84. Lucke KH, Laqua H. Silicone Oil in the Treatment of Complicated Retinal Detachments. Berlin: Springer-Verlag; 1990;
  85. Machemer R. Retinotomy. Am J Ophthalmol. 1981;92:768–774
  86. Machemer R. Pathogenesis and classification of massive periretinal proliferation. Br J Ophthalmol. 1978;62:737–747
  87. Machemer R, Aaberg TM, Freeman M, et al.  An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159–165
  88. Madelcon MS, Machemer R, Fineberg E, Hersch SB. Proliferation and metaplasia of intravitreal retinal pigment epithelium cell autotransplants. Am J Ophthalmol. 1975;80:227–237
  89. Martini B. Proliferative vitreo-retinal disorders (Experimental models in vivo and in vitro). Acta Ophthalmol. 1992;201(Suppl):1–63
  90. McCuen BW, De Juan E, Landers MB, et al.  Silicone oil in vitreoretinal surgery (II. Results and complications). Retina. 1985;5:198–205
  91. McCuen BW, Hida T, Sheta SM. Transvitreal cyanoacrylate retinopexy in the management of complicated retinal detachment. Am J Ophthalmol. 1987;104:127–132
  92. Michels R, Wilkinson C, Rice TA. Retinal Detachment. St Louis: CV Mosby; 1990;
  93. Mietz H, Heimann K. Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal diseases. Br J Ophthalmol. 1995;79:874–877
  94. Mietz H, Walshe R, Widemann P, et al.  Histopathologic study of epiretinal proliferations after vitrectomy with daunomycin and silicone oil. Retina. 1994;14:425–429
  95. Miller B, Miller H, Patterson R, Ryan SJ. Retinal wound healing. Cellular activity at the vitreoretinal interface. Arch Ophthalmol. 1986;104:281–285
  96. Miyamoto K, Refojo MF, Tolentino FI, et al.  Fluorinated oils as experimental vitreous substitutes. Arch Ophthalmol. 1986;104:1053–1056
  97. Nomoto A, Mutoh S, Hagihara H, Yamaguchi I. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis. 1988;72:213–219
  98. Ohsato M, Shiga S, Kato H, et al.  Immunohistochemical study of cellular fibronectin in preretinal membranes. Retina. 1994;14:430–434
  99. Ohuchi T, Kuriyama S, Yoshimura N, et al.  Suppression of human retinal pigment epithelial cell proliferation by hyperthermia. Arch Ophthalmol. 1990;108:873–875
  100. Olesza EL. Inhibition of mitogenic activity of PDGF, EGF and FGF by interferon gamma. Exp Cell Res. 1988;179:575–580
  101. Pastor JC, López MI, Saornil MA, et al.  Intravitreal silicone and fluorosilicone oils (Pathologic findings in rabbit eyes). Acta Ophthalmol. 1992;70:651–658
  102. Peyman GA, Shulman JA. Vitreous Substitutes. East Norwalk: Appleton and Lange; 1995;
  103. Piñon R, Pastor JC, Saornil MA, et al.  Intravitreal and subretinal proliferation induced by platelet-rich plasma injection in rabbits. Curr Eye Res. 1992;11:1047–1055
  104. Piñon R, Pastor JC, Saornil MA, et al.  Estudio experimental del efecto de la inyección intravı́trea de plasma rico en plaquetas asociada a crioaplicación y vitrectomı́a. Arch Soc Esp Oftalmol. 1991;63:313–320
  105. Piñon R, Saornil MA, Goldaracena MB, et al.  Estudio experimental del efecto de la inyección intravı́trea del plasma rico en plaquetas. Resultados preliminares. Arch Soc Esp Oftalmol. 1989;57:555–564
  106. Raymond L, Jacobson B. Isolation and identification of stimulatory and inhibitory cell growth factors in bovine vitreous. Exp Eye Res. 1982;34:267–286
  107. The Retina Society Terminology Committee . The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121–125
  108. Ryan SJ. Traction retinal detachment. XLIX Edward Jackson Memorial Lecture. Am J Ophthalmol. 1993;115:1–20
  109. Ryan SJ. The pathophysiology of proliferative vitreoretinopathy and its management. Am J Ophthalmol. 1985;100:188–193
  110. Scheiffarth OF, Kampik A, Gunther-Koszka H, Von der Mark K. Collagens, fibronectin and laminin in proliferative vitreoretinopathy. In:  Heimann K,  Wiedemann P editor. Proliferative Vitreoretinopathy. Heidelberg: Kaden; 1989;p. 134–138
  111. Schultz GS, Grant MB. Neovascular growth factors. Eye. 1991;5:170–180
  112. Scott JD. Pathogenesis of PVR with analysis of events leading to recurrent retinal detachment. In:  Heimann K,  Wiedemann P editor. Proliferative Vitreoretinopathy. Heidelberg: Kaden; 1989;p. 150–153
  113. Sebag J, Tang M. Pneumatic retinopexy using only air. Retina. 1993;13:8–12
  114. The Silicone Study Group . Postoperative intraocular pressure abnormalities in the Silicone Study. Silicone Study Report 4. Ophthalmology. 1993;100:1629–1635
  115. The Silicone Study Group: Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 3. Retina 13:279–284, 1993
  116. The Silicone Study Group: Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: Results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol 110:780–792, 1992
  117. The Silicone Study Group: Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: Results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol 110:770–779, 1992
  118. Smiddy WE, Glaser BM, Green WR, et al.  Transforming growth factor beta. A biologic chorioretinal glue. Arch Ophthalmol. 1989;107:577–680
  119. Smith LEH, Aiello LP, Foley ED, et al.  Inhibition of proliferative retinopathy using antisense phosphorothioate olignucleotides against vascular endothelial growth factor (VEGF/VPF) (abstract). Invest Ophthalmol Vis Sci. 1995;36(Suppl):S871
  120. Souza OF, Sakamoto T, Kimura H, et al.  Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin. Ophthalmologica. 1995;209:211–216
  121. Steinhorst U, Chen EP, Hatchell DL, et al.  Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1993;34:1753–1760
  122. Steinhorst U, Chen EP, Machemer R, Hatchell DL. N,N-Dimethyladriamycin for treatment of experimental vitreoretinopathy (Efficacy and toxicity on the rabbit retina). Exp Eye Res. 1993;56:489–495
  123. Stolba U, Binder S, Velikay M, et al.  Use of perfluorocarbon liquids in proliferative vitreoretinopathy (results and complications). Br J Ophthalmol. 1995;79:1106–1110
  124. Stout T, Kimura H, Sakamoto T, et al.  Gene therapy for proliferative vitreoretinopathy. Exp Eye Res. 1996;63(Suppl):S12
  125. Tang S, Scheiffarth OF, Wildner G, et al.  Lymphocytes, macrophages and HLA-DR expression in vitreal and epiretinal membranes of proliferative vitreoretinopathy. An immunohistochemical study. Ger J Ophthalmol. 1992;1:176–179
  126. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90:810–816
  127. Uram M. Laser endoscope in the management of proliferative vitreoretinopathy. Ophthalmology. 1994;101:1404–1408
  128. Velikay M, Wedrich A, Stolba U, et al.  Experimental long-term vitreous replacement with purified and nonpurified perfluorodecalin. Am J Ophthalmol. 1993;116:565–570
  129. Vidauri-Leal J, Hohman R, Glaser BM. Effect of vitreous on morphologic characteristics of retinal pigment epithelial cells. A new approach to the study of proliferative vitreoretinopathy. Arch Ophthalmol. 1984;102:1220–1223
  130. Ward T, Hartzer M, Blumenkranz M, Lin L. A comparison of 5-fluorouridine and 5-fluorouracil in an experimental model for the treatment of vitreoretinal scarring. Curr Eye Res. 1993;12:397–401
  131. Weller M, Wiedemann P, Heimann K. Proliferative vitreoretinopathy. Is it anything more than wound healing at the wrong place?. Int Ophthalmol. 1990;14:105–117
  132. Wiedemann P. Growth factors in retinal diseases (proliferative vitreoretinopathy, proliferative diabetic retinopathy and retinal degeneration). Surv Ophthalmol. 1992;36:373–384
  133. Wiedemann P, Evans PY, Widemann R, et al.  A fluorescein angiographic study on patients with proliferative vitreoretinopathy treated by vitrectomy and intraocular daunomycin. Int Ophthalmol. 1989;13:211–216
  134. Wiedemann P, Leinung C, Hilgers RD, Heimann K. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991;229:150–152
  135. Wiedemann P, Weller M. The pathophysiology of proliferative vitreoretinopathy. Acta Ophthalmol. 1988;189(Suppl):3–15
  136. Wilkins RB, Kulwin DR. Wound healing. Ophthalmology. 1979;86:507–510
  137. Williams GA, Lambrou FH, Jaffe GA, et al.  Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol. 1988;106:1055–1058
  138. Yang CH, Cousins S. Quantitative assessment of growth stimulating activity of the vitreous during PVR. Invest Ophthalmol Vis Sci. 1992;33:2436–2442
  139. Yang CH, Huang TF, Liu KR, et al.  Inhibition of retinal pigment epithelial cell-induced tractional detachment by disintegrins, a group of Arg-Gly-Asp-containing peptides from viper venom. Invest Ophthalmol Vis Sci. 1996;37:843–854

PII: S0039-6257(98)00023-X

Survey of Ophthalmology
Volume 43, Issue 1 , Pages 3-18 , July 1998

Article Tools

* Image Usage & Resolution